FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809815511> ?p ?o ?g. }

• W2809815511 abstract "Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of advanced pancreatic cancer following progression on gemcitabine-based chemotherapy. There are limited additional data on the safety and efficacy of nal-IRI + 5-FU/LV following FDA approval in October 2015. We examined the post-approval safety and effectiveness of nal-IRI + 5-FU/LV in advanced pancreatic cancer patients receiving treatment at Memorial Sloan Kettering Cancer Center.A retrospective chart review was conducted of all patients beginning treatment with nal-IRI + 5-FU/LV from October 2015 through June 2017. Using the electronic medical record and institutional database, information was extracted pertaining to demographics, performance status (ECOG), prior therapies, dose, duration of treatment, adverse events, progression free survival (PFS), overall survival (OS) and treatment response.Fifty six patients were identified. Median progression free survival (PFS) was 2.9 months and median overall survival (OS) was 5.3 months. Patients with prior disease progression on irinotecan experienced PFS and OS of 2.2 and 3.9 mo, respectively. Patients without prior irinotecan exposure experienced significantly longer PFS (4.8 mo, p = 0.02) and OS (7.7 mo, p = 0.002), as did patients who received prior irinotecan without disease progression (PFS, 5.7 mo, p = 0.04; OS, 9.0 mo, p = .04). Progression on prior irinotecan was associated with greater lines of prior advanced disease chemotherapy (2 vs 1). Dose reductions (DR) were most frequently due to fatigue (42%) and diarrhea (37%), but were not associated with worse outcomes. In fact, patients with ≥1 DR experienced longer PFS (5.4 v 2.6 mo, p = 0.035). Sequential therapy with nab-paclitaxel + gemcitabine (nab-P + Gem) followed by nal-IRI + 5-FU/LV (n = 25) resulted in OS of 23.0 mo. Mutations in TP53 were associated with shorter PFS.These data support the safety and efficacy of nal-IRI + 5-FU/LV, reinforcing results of NAPOLI-1. Patients without disease progression on prior irinotecan fared significantly better than patients with progression, when treated with nal-IRI + 5-FU/LV. Sequential therapy with nab-P + Gem followed by nal-IRI + 5-FU/LV demonstrates encouraging median OS. These findings provide guidance for patients most likely to benefit from nal-IRI + 5-FU/LV." @default.
• W2809815511 created "2018-07-10" @default.
• W2809815511 creator A5009446517 @default.
• W2809815511 creator A5027280259 @default.
• W2809815511 creator A5027467209 @default.
• W2809815511 creator A5034269529 @default.
• W2809815511 creator A5047405633 @default.
• W2809815511 creator A5065435809 @default.
• W2809815511 creator A5068026508 @default.
• W2809815511 creator A5074144766 @default.
• W2809815511 creator A5076438320 @default.
• W2809815511 creator A5091826467 @default.
• W2809815511 date "2018-06-27" @default.
• W2809815511 modified "2023-10-15" @default.
• W2809815511 title "Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience" @default.
• W2809815511 cites W1968812902 @default.
• W2809815511 cites W1987313243 @default.
• W2809815511 cites W1991592278 @default.
• W2809815511 cites W2005021386 @default.
• W2809815511 cites W2006766434 @default.
• W2809815511 cites W2008532487 @default.
• W2809815511 cites W2019067973 @default.
• W2809815511 cites W2041354095 @default.
• W2809815511 cites W2066861571 @default.
• W2809815511 cites W2072714492 @default.
• W2809815511 cites W2138155367 @default.
• W2809815511 cites W2151253787 @default.
• W2809815511 cites W2158798157 @default.
• W2809815511 cites W2161884651 @default.
• W2809815511 cites W2165480504 @default.
• W2809815511 cites W2169895148 @default.
• W2809815511 cites W2187917981 @default.
• W2809815511 cites W2285093314 @default.
• W2809815511 cites W2321478288 @default.
• W2809815511 cites W2345269414 @default.
• W2809815511 cites W2470015644 @default.
• W2809815511 cites W2472707660 @default.
• W2809815511 cites W2518765238 @default.
• W2809815511 cites W2548931019 @default.
• W2809815511 cites W2570618306 @default.
• W2809815511 cites W2573972894 @default.
• W2809815511 cites W2594962867 @default.
• W2809815511 cites W2610989131 @default.
• W2809815511 cites W2735949777 @default.
• W2809815511 cites W2740722982 @default.
• W2809815511 cites W2749989634 @default.
• W2809815511 cites W2753565653 @default.
• W2809815511 cites W2797040438 @default.
• W2809815511 cites W4229987800 @default.
• W2809815511 doi "https://doi.org/10.1186/s12885-018-4605-1" @default.
• W2809815511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6020418" @default.
• W2809815511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29945562" @default.
• W2809815511 hasPublicationYear "2018" @default.
• W2809815511 type Work @default.
• W2809815511 sameAs 2809815511 @default.
• W2809815511 citedByCount "62" @default.
• W2809815511 countsByYear W28098155112019 @default.
• W2809815511 countsByYear W28098155112020 @default.
• W2809815511 countsByYear W28098155112021 @default.
• W2809815511 countsByYear W28098155112022 @default.
• W2809815511 countsByYear W28098155112023 @default.
• W2809815511 crossrefType "journal-article" @default.
• W2809815511 hasAuthorship W2809815511A5009446517 @default.
• W2809815511 hasAuthorship W2809815511A5027280259 @default.
• W2809815511 hasAuthorship W2809815511A5027467209 @default.
• W2809815511 hasAuthorship W2809815511A5034269529 @default.
• W2809815511 hasAuthorship W2809815511A5047405633 @default.
• W2809815511 hasAuthorship W2809815511A5065435809 @default.
• W2809815511 hasAuthorship W2809815511A5068026508 @default.
• W2809815511 hasAuthorship W2809815511A5074144766 @default.
• W2809815511 hasAuthorship W2809815511A5076438320 @default.
• W2809815511 hasAuthorship W2809815511A5091826467 @default.
• W2809815511 hasBestOaLocation W28098155111 @default.
• W2809815511 hasConcept C121608353 @default.
• W2809815511 hasConcept C126322002 @default.
• W2809815511 hasConcept C143998085 @default.
• W2809815511 hasConcept C197934379 @default.
• W2809815511 hasConcept C2776694085 @default.
• W2809815511 hasConcept C2778822529 @default.
• W2809815511 hasConcept C2779984678 @default.
• W2809815511 hasConcept C2780210213 @default.
• W2809815511 hasConcept C2780258809 @default.
• W2809815511 hasConcept C2780259306 @default.
• W2809815511 hasConcept C2780456651 @default.
• W2809815511 hasConcept C2780739268 @default.
• W2809815511 hasConcept C526805850 @default.
• W2809815511 hasConcept C71924100 @default.
• W2809815511 hasConceptScore W2809815511C121608353 @default.
• W2809815511 hasConceptScore W2809815511C126322002 @default.
• W2809815511 hasConceptScore W2809815511C143998085 @default.
• W2809815511 hasConceptScore W2809815511C197934379 @default.
• W2809815511 hasConceptScore W2809815511C2776694085 @default.
• W2809815511 hasConceptScore W2809815511C2778822529 @default.
• W2809815511 hasConceptScore W2809815511C2779984678 @default.
• W2809815511 hasConceptScore W2809815511C2780210213 @default.
• W2809815511 hasConceptScore W2809815511C2780258809 @default.
• W2809815511 hasConceptScore W2809815511C2780259306 @default.
• W2809815511 hasConceptScore W2809815511C2780456651 @default.
• W2809815511 hasConceptScore W2809815511C2780739268 @default.
• W2809815511 hasConceptScore W2809815511C526805850 @default.

• next